← Back
Data updated: Jun 28, 2026
CLIVUNEL INC
Pharma Pharmaceuticals
CLIVUNEL INC is a pharmaceutical company with 1 FDA-approved products.
2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2019) 1 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2019 SCENESSE (AFAMELANOTIDE) First-in-Class · Orphan · Priority Review · Fast Track
CLIVUNEL INC's Key Drugs
CLIVUNEL INC's core commercial portfolio centers on SCENESSE — its most strategically important drugs approved in the last 15 years.
CLIVUNEL INC's Recent FDA Approvals
New NDA/BLA approvals for CLIVUNEL INC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
CLIVUNEL INC's Therapeutic Areas
Disease areas where CLIVUNEL INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
CLIVUNEL INC Pipeline Snapshot
Active clinical trials for CLIVUNEL INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SCENESSE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-10-08
- Latest
- 2024-08-12
- Applications
- 1